Zeo Scientifix, Inc income statement ZEOX

Annual Quarterly

In fiscal 2026, which ended Oct 31, 2025, Zeo Scientifix, Inc reported revenue of $5.2 million. It recorded a net loss of $5.5 million. The operating loss came to $5.4 million, an operating margin of -103.6%. Diluted earnings per share were -$0.86. Across the 10 fiscal years shown, revenue grew from $184,881 in fiscal 2016 to $5.2 million in fiscal 2026, about 44.9% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line	FY 2026 Apr 30, 2026	FY 2026 Oct 31, 2025	FY 2024 Oct 31, 2024	FY 2023 Oct 31, 2023	FY 2022 Oct 31, 2022	FY 2021 Oct 31, 2021	FY 2020 Oct 31, 2020	FY 2019 Oct 31, 2019	FY 2018 Oct 31, 2018	FY 2017 Oct 31, 2017	FY 2016 Oct 31, 2016
Revenue	—	5	5 +1.4%	5 -29.8%	6 +16.0%	6 +83.2%	3 +79.5%	2 +76.5%	1 +69.3%	1 +208.2%	0 +25.2%
Cost of revenue	—	1	1 +66.1%	1 -32.6%	1 +37.5%	1 +37.4%	0 +32.5%	0 +43.7%	0 +30.3%	0 +70.2%	0 +91.1%
Gross profit	—	4	4 -6.8%	4 -29.4%	6 +13.6%	5 +90.0%	3 +89.6%	1 +85.6%	1 +84.6%	0 +352.3%	0 -7.9%
Research and development	—	0	—	1 +16.6%	1 -29.4%	1 +379.6%	0	—	—	—	—
Selling, general and administrative	—	10	9 -15.9%	11 -25.8%	15 -18.1%	18 +17.9%	15 +375.0%	3 -25.1%	4 -53.1%	9 +698.3%	1 +34.6%
Operating income	—	-5	-5 +21.4%	-7 +23.5%	-9 +30.6%	-13 -2.5%	-12 -600.1%	-2 +49.1%	-3 +59.6%	-9 -728.3%	-1
Pretax income	—	—	—	—	-9 +30.3%	-13 -1.4%	-13 -623.9%	-2 +49.3%	-3	—	—
Income tax	—	—	—	—	—	0	0	0	0	0	—
Net income	—	-6	-5 +32.7%	-7 +21.5%	-9 +30.3%	-13 -1.4%	-13 -624.3%	-2 +49.8%	-3 +61.4%	-9 -615.9%	-1 -69.7%
Basic EPS	—	-0.86	-0.74 +25.3%	-0.99	—	—	—	—	—	—	—
Diluted EPS	—	-0.86	-0.74 +25.3%	-0.99	—	—	—	—	—	—	—
Weighted average shares, basic	—	6	6 -9.8%	7	—	—	—	—	—	—	—
Weighted average shares, diluted	—	6	6 -9.8%	7	—	—	—	—	—	—	—
Other measures
Depreciation and amortization	—	0	0 -84.8%	0 +46.2%	0 +530.9%	0 +43.3%	0 +148.6%	0 +88.8%	0 -59.4%	0 +5498.6%	0 +301.2%
EBITDA	—	-5	-5 +16.5%	-6 +26.2%	-9 +32.9%	-13 -2.3%	-12 -603.9%	-2 +49.4%	-3 +59.6%	-9 -726.7%	-1
Interest coverage	—	-54.96x	-57.82x	-15.70x	-22.20x	—	-69.98x	-38.12x	-15.29x	-15.00x	—
Margins
Gross margin	—	82.09%	81.73%	88.85%	88.39%	90.21%	86.96%	82.33%	78.30%	71.81%	48.94%
Operating margin	—	-103.60%	-115.13%	-148.49%	-136.23%	-227.68%	-407.03%	-104.36%	-361.85%	-1,516.47%	-564.32%
Pretax margin	—	—	—	—	-137.06%	-227.90%	-411.78%	-102.12%	-355.76%	—	—
Profit margin	—	-106.19%	-101.84%	-153.29%	-137.06%	-227.90%	-411.78%	-102.06%	-358.95%	-1,574.49%	-677.84%
EBITDA margin	—	-102.19%	-113.53%	-137.82%	-131.11%	-226.73%	-405.83%	-103.49%	-361.03%	-1,513.08%	-564.13%

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: ZEOX (OTC)
Fiscal year ends: June 30
Incorporated in: NV
Headquarters: Davie, FL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1557376
Former names: Organicell Regenerative Medicine, Inc. (until Jan 29, 2024); Biotech Products Services & Research, Inc. (until Jun 15, 2018); BESPOKE TRICYCLES INC (until Sep 14, 2015)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.